Summit Therapeutics Inc Ordinary Shares SMMT
News
Summit Therapeutics' stock pops as lung-cancer treatment beats Merck blockbuster in late-stage trial
Ivonescimab Monotherapy Reduced the Risk of Disease Progression or Death by 49% Compared to Pembrolizumab Monotherapy in First-Line Treatment of Patients with PD-L1 Positive Advanced NSCLC in China
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
HARMONi-2, Featuring Ivonescimab Monotherapy vs. Pembrolizumab Monotherapy, to be Showcased in Presidential Symposium at WCLC 2024
Two Ivonescimab (PD-1/VEGF) Results including Phase 3 Monotherapy versus Pembrolizumab Monotherapy in First-Line Treatment for PD-L1 Positive NSCLC to Be Presented at WCLC 2024
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2024
Summit Therapeutics to Host Second Quarter 2024 Financial Results & Operational Progress Call on August 6, 2024
Summit Therapeutics and MD Anderson Announce Strategic Collaboration to Accelerate Development of Ivonescimab
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Summit Therapeutics' stock surges as lung-cancer treatment vies with Merck's blockbuster
Summit Therapeutics Shares Triple After Drug Candidate Data